This report describes the results of an analysis of patient-reported outcomes from EMILIA ( TDM@g/BO@ ) , a randomized phase @ study of the antibody-drug conjugate trastuzumab emtansine ( T-DM@ ) versus capecitabine and lapatinib in human epidermal growth factor receptor @ ( HER@ ) - positive locally advanced or metastatic breast cancer .